NEJM: Survival with Osimertinib plus Chemotherapy in EGFR-Mutated Advanced NSCLC

This clinical study investigates whether combining the targeted drug osimertinib with traditional chemotherapy offers a superior outcome for patients facing a specific type of advanced lung cancer. By comparing this dual approach against the standard single-drug therapy, researchers discovered that the combination treatment significantly extended the livesof participants by nearly ten months. While the combined regimen proved more effective at keeping the disease at bay, it also resulted in a higher frequency of severe side effects compared to the solo medication. Ultimately, the trial demonstrates a clear survival advantage for this aggressive frontline strategy, providing a more potent but more intensive option for managing this complex malignancy.